MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562848261458694

Медицинская библиотека · Therapeutic advances in gastroenterology · 2026

Upadacitinib for anti-TNFα refractory immune checkpoint inhibitor-induced colitis: a case report.

Petrousis Grigorios, Hedin Charlotte R H, Haas Stephan L, Strid Hans, Bresso Francesca, Bilén Katarina

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Although immune checkpoint inhibitors have revolutionized oncologic therapy, they are frequently associated with a wide spectrum of immune-related adverse events, most notably immune-mediated colitis (ImC). For cases of moderate-to-severe colitis, treatment typically involves corticosteroids with escalation to biologic agents such as infliximab or vedolizumab when necessary. However, treatment-refractory cases remain a major clinical challenge. We report the case of a 52-year-old woman with triple-negative breast cancer who developed severe ImC after pembrolizumab therapy. Despite high-dose corticosteroids and infliximab, her condition remained refractory. Initiation of upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, led to rapid clinical improvement and complete endoscopic remission of the colitis. This report highlights the therapeutic potential of upadacitinib against ImC, while also analysing the possible twofold role of JAK1-inhibitors in enhancing antitumour therapy efficacy and limiting the potential immune-related adverse events.

Для цитирования: Petrousis Grigorios, Hedin Charlotte R H, Haas Stephan L, Strid Hans, Bresso Francesca, Bilén Katarina. Upadacitinib for anti-TNFα refractory immune checkpoint inhibitor-induced colitis: a case report.. Therapeutic advances in gastroenterology. 2026. DOI: 10.1177/17562848261458694.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.